Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial
Health Engagement for Rural Ohio Cancer Survivors (HERO-C)
Studienübersicht
Status
Bedingungen
- Anatomischer Brustkrebs im Stadium I AJCC v8
- Anatomischer Brustkrebs im Stadium II AJCC v8
- Anatomischer Brustkrebs im Stadium III AJCC v8
- Endometriumkarzinom
- Karzinom im Stadium III Uterine Corpus oder Karzinosarkom AJCC V8
- Stadium I Uterine Corpus -Karzinom oder Karzinosarkom AJCC V8
- Karzinom im Stadium II Uterine Corpus oder Karzinosarkom AJCC V8
Intervention / Behandlung
- Sonstiges: Fragebogenverwaltung
- Verfahren: Sammlung von Bioproben
- Sonstiges: Aerobic Exercise
- Sonstiges: Dietary Intervention
- Sonstiges: Discussion
- Sonstiges: Internet-Based Intervention
- Sonstiges: Resistance Training
- Sonstiges: Supportive Care
- Sonstiges: Supportive Care
- Sonstiges: Goal Setting
- Sonstiges: Medical Device Usage and Evaluation
- Verhalten: Smartphone Application-based Intervention
- Verfahren: Tailored Intervention
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To determine the feasibility of an mHealth + EMA intervention in addition to the web-based lifestyle program with remote outcome assessments among rural breast and endometrial cancer survivors. (Aim 1) Ia. To identify rural cancer survivors' perspectives and unique needs/challenges of participating in a web-based lifestyle program via focus groups pre- and post-intervention (n=20); (Aim 1a) Ib. To determine the feasibility of mHealth + EMA among early non-responders (week 5-26); (Aim 1b) Ic. To determine the feasibility of remote outcome assessments. (Aim 1c) II. To determine the preliminary efficacy of the additional mHealth + EMA intervention for early non-responders from the web-based lifestyle program (within-person change from week 5-26). (Aim 2)
EXPLORATORY OBJECTIVE:
I. To explore the differences in metabolomic, inflammatory, behavioral, and psychosocial factors between early responders and early non-responders at baseline, month 1 and month 6.
OUTLINE:
PHASE I (WEEKS 1-4): Patients complete self-paced web-based lifestyle program modules over 45-90 minutes weekly for 4 weeks. Patients adhere to a personalized diet meeting American Institute of Cancer Research (AICR) guidelines and receive access to online resources, including AICR resources, online cooking class videos, healthy eating recipes and tips. Patients participate in moderate-intensity aerobic physical activity over 10-30 minutes on 5 days weekly and resistance training over 30 minutes on 2-3 times weekly.
PHASE II (WEEKS 5-26): Patients are assigned to 1 of 2 groups based on Phase I progress.
GROUP I (EARLY RESPONDER): Patients continue web-based program modules, exercise program and diet recommendations as in Phase I. Patients also attend virtual group sessions over 45-50 minutes weekly for weeks 5-26.
GROUP II (EARLY NON-RESPONDER): Patients continue web-based program modules, exercise program and diet recommendations as in Phase I. Patients also set goals for behavioral changes weekly and receive just-in-time adaptive interventions (JITAI) tailored resource components via mHealth + EMA during weeks 5-26. Patients wear a physical activity tracker daily and receive access to the Fitbit application (App).
Patients may also participate in a focus group over 30-45 minutes on study. Additionally, patients undergo urine and blood sample collection throughout the study.
After completion of study intervention, patients may follow up in 6 months.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: The Ohio State University Comprehensive Cancer Center
- Telefonnummer: 800-293-5066
- E-Mail: OSUCCCClinicaltrials@osumc.edu
Studienorte
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
Kontakt:
- Xiaochen Zhang, PhD
- Telefonnummer: 614-685-0624
- E-Mail: Xiaochen.Zhang@osumc.edu
-
Hauptermittler:
- Xiaochen Zhang, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Body mass index (BMI) ≥ 25kg/m^2
- Age: 40-69 years
- 1-5 years post-diagnosis of stage I-III postmenopausal breast cancer or stage I-III endometrial cancer
- No known evidence of recurrence (local or distant) or second, primary cancer
- No prior history of new other malignancy since their breast or endometrial cancer diagnosis (other than non-melanoma skin cancer)
- Not currently participating in any weight loss programs, no personal trainer, and not meeting the physical activity guidelines
- No use of any anti-obesity medications in the last 6 months and no plan to start anti-obesity medications during the study period
- The ability to walk two blocks without a walker or cane
- The ability to speak and read English
- Have access to internet with a computer, tablet, or smart phone
- Live in rural counties in Ohio and not planning to move away during the study
- Are not pregnant, breastfeeding or less than 12-month post-partum and do not plan to become pregnant during the study
Exclusion Criteria:
- Severe medical conditions, such as unstable cardiovascular disease or digestive disorders, that would preclude physical activity and dietary intervention
- Lack of physician clearance if determined necessary by the Physical Activity Readiness Questionnaire (PAR-Q+)
- Acute physical limitations for unsupervised exercises at home
- Unable to give informed consent
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Group I (web-based lifestyle program, virtual group)
PHASE I (WEEKS 1-4): Patients complete self-paced web-based lifestyle program modules over 45-90 minutes weekly for 4 weeks. Patients adhere to a personalized diet meeting AICR guidelines and receive access to online resources, including AICR resources, online cooking class videos, healthy eating recipes and tips. Patients participate in moderate-intensity aerobic physical activity over 10-30 minutes on 5 days weekly and resistance training over 30 minutes on 2-3 times weekly. PHASE II (WEEKS 5-26): Patients continue web-based program modules, exercise program and diet recommendations as in Phase I. Patients also attend virtual group sessions over 45-50 minutes weekly for weeks 5-26. Patients may also participate in a focus group over 30-45 minutes on study. Additionally, patients undergo urine and blood sample collection throughout the study. |
Nebenstudien
Lassen Sie sich Urin- und Blutproben entnehmen
Andere Namen:
Participate in moderate-intensity aerobic physical activity
Andere Namen:
Adhere to a personalized diet
Andere Namen:
Participate in a focus group
Andere Namen:
Complete self-paced web-based lifestyle program modules
Participate in resistance training
Andere Namen:
Receive access to online resources
Andere Namen:
Attend virtual group sessions
Andere Namen:
|
|
Experimental: Group II (web-based lifestyle, JITAI)
PHASE I (WEEKS 1-4): Patients complete self-paced web-based lifestyle program modules over 45-90 minutes weekly for 4 weeks. Patients adhere to a personalized diet meeting AICR guidelines and receive access to online resources, including AICR resources, online cooking class videos, healthy eating recipes and tips. Patients participate in moderate-intensity aerobic physical activity over 10-30 minutes on 5 days weekly and resistance training over 30 minutes on 2-3 times weekly. PHASE II (WEEKS 5-26): Patients continue web-based program modules, exercise program and diet recommendations as in Phase I. Patients also set goals for behavioral changes weekly and receive JITAI tailored resource components via mHealth + EMA during weeks 5-26. Patients wear a physical activity tracker daily and receive access to the Fitbit App. Patients may also participate in a focus group over 30-45 minutes on study. Patients undergo urine and blood sample collection throughout the study. |
Nebenstudien
Lassen Sie sich Urin- und Blutproben entnehmen
Andere Namen:
Participate in moderate-intensity aerobic physical activity
Andere Namen:
Adhere to a personalized diet
Andere Namen:
Participate in a focus group
Andere Namen:
Complete self-paced web-based lifestyle program modules
Participate in resistance training
Andere Namen:
Receive access to online resources
Andere Namen:
Attend virtual group sessions
Andere Namen:
Set goals for behavioral changes
Wear a physical activity tracker
Receive access to the Fitbit app
Andere Namen:
Receive JITAI tailored resource components
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Preferences, needs and satisfaction (Aim 1a)
Zeitfenster: At pre- and post-intervention, assessed up to week 26
|
Focus groups will be audio recorded through online videoconference (e.g.
Teams) and transcribed using NVivo.
Content analysis will be conducted to identify patterns, themes, and perspectives from participants using NVivo coding or similar software.
When possible, the frequency, intensity, and context of certain perspectives will be described.
Similarly, thematic analysis will be conducted using NVivo to identify themes (e.g., likes/dislikes, motivations, expectations) and mapped to potential intervention components.
|
At pre- and post-intervention, assessed up to week 26
|
|
Percentage of early non-responders who complete the mobile Health + ecological momentary assessment intervention (Aim 1b)
Zeitfenster: Up to week 26
|
Will report the frequency, proportion, and 95% confidence intervals (CIs) of early non-responders who completed the intervention.
|
Up to week 26
|
|
Percentage of all participants who complete all assessments (Aim 1c)
Zeitfenster: Up to week 26
|
Will report the frequency, proportion, and 95% CIs of all participants who completed outcome assessments.
|
Up to week 26
|
|
Changes in weight (Aim 2)
Zeitfenster: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Linear mixed models will be used to account for repeated measures, with random effects for the individual.
The linear mixed models will use all available data under a missing-at-random assumption and will assess potential attrition bias by comparing baseline/week 4 characteristics of completers versus non-completers, with sensitivity analyses is missingness appears outcome-related.
Will report the preliminary effect size as within-person changes on weight (from week 4 to week 26).
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
|
Changes in muscle mass (Aim 2)
Zeitfenster: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Will estimate the preliminary effect size using linear mixed models.
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
|
Changes in metabolic profiles (Aim 2)
Zeitfenster: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Will estimate the preliminary effect size using linear mixed models.
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
|
Changes in inflammatory markers (Aim 2)
Zeitfenster: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Will estimate the preliminary effect size using linear mixed models.
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
|
Changes in behaviors (Aim 2)
Zeitfenster: At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Will estimate the preliminary effect size using linear mixed models.
|
At baseline (T0), at week 4 (T1), and at week 26 (T2)
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Xiaochen Zhang, PhD, Ohio State University Comprehensive Cancer Center
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Neubildungen nach histologischem Typ
- Uteruserkrankungen
- Genitalerkrankungen, weiblich
- Genitale Neubildungen, weiblich
- Uterusneoplasmen
- Sarkom
- Neubildungen, Binde- und Weichgewebe
- Neubildungen, komplex und gemischt
- Endometriale Neubildungen
- Karzinosarkom
- Organisation und Verwaltung
- Verwaltung des Gesundheitswesens
- Motorik
- Bewegung
- Phänomen des Bewegungsapparates muskuloskelettal
- Muskuloskelettaler und neuronales physiologisches Phänomen
- Untersuchungstechniken
- Therapeutika
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Physiotherapiemodalitäten
- Patientenversorgung
- Gesundheitsdienste
- Belegschaft und Dienstleistungen für Gesundheitseinrichtungen
- Trainingstherapie
- Rehabilitation
- Nachbehandlung
- Kontinuität der Patientenversorgung
- Ernährungstherapie
- Körperliche Kondition, menschlich
- Übung
- Palliativpflege
- Handhabung von Proben
- Widerstandstraining
- Diättherapie
- Organisationsziele
Andere Studien-ID-Nummern
- OSU-26016
- NCI-2026-05189 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- STUDY20252952
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .